No Improvement of Adult Height in Non-growth Hormone (GH) Deficient Short Children with GH Treatment.
It is still in doubt whether the standard-dose growth hormone (GH) used in Japan (0.5 IU/kg/week, 0.167 mg/kg/week) for growth hormone deficiency is effective for achieving significant adult height improvement in non-growth hormone deficient (non-GHD) short children. We compared the growth of GH-treated non-GHD short children with that of untreated short children to examine the effect of standard-dose GH treatment on non-GHD short children. GH treatment with recombinant human growth hormone (rhGH) was started before the age of 11 yr in 64 boys and 76 girls with non-GHD short stature registered at the Foundation for Growth Science who have now reached their adult height. In 119 untreated boys and 127 untreated girls whose height standard deviation score (SDS) was below -2 SD at the age of 6 yr, height growth was followed until 17 yr. Height SDS was significantly lower before GH treatment in the GH-treated group than at the age of 6 yr in the untreated group, in both sexes. Adult height and adult height SDS were significantly greater in the untreated group than in the GH-treated group, in both sexes, although the change in height SDS did not differ significantly. Height SDS was significantly lower before GH treatment in the GH-treated group than at the age of 6 yr in the untreated group, so 57 boys and 57 girls whose height SDS at the age of 6 yr in the untreated group closely matched the height SDS before GH treatment in the GH-treated group were chosen for comparison. Height SDS did not differ significantly between the GH-treated group before GH treatment and the untreated group at the age of 6 yr, nor were there differences between these subgroups in adult height, adult height SDS, or height SDS change, in either sex. The effect of GH treatment is reported to be dose-dependent and doses over 0.23 mg/kg/week are reported to be necessary to improve adult height in non-GHD short children. Currently, the GH dose is fixed at 0.175 mg/kg/week in Japan, and we expected to find, and indeed concluded, that ordinary GH treatment in Japanese, non-GHD short children does not improve adult height.
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan ; Department of Clinical Laboratory Medicine, National Center for Child Health and Development, Tokyo, Japan.
Toshiaki
T
Tanaka
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Kenji
K
Fujieda
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Susumu
S
Yokoya
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Akira
A
Shimatsu
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Katsuhiko
K
Tachibana
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Hiroyuki
H
Tanaka
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Takakuni
T
Tanizawa
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Akira
A
Teramoto
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Toshiro
T
Nagai
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Yoshikazu
Y
Nishi
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Yukihiro
Y
Hasegawa
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Kunihiko
K
Hanew
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Keinosuke
K
Fujita
Study Group of Growth Hormone Treatment, the Foundation for Growth Science, Japan.
Reiko
R
Horikawa
Akita University, Akita, Japan.
Goro
G
Takada
Akita Red Cross Hospital, Akita, Japan.
Masao
M
Miyashita
Ohno Clinic, Akita, Japan.
Tadashi
T
Ohno
Akita Kumiai General Hospital, Akita, Japan.
Kazuo
K
Komatsu
GH dosage; GH treatment; non-GHD short children